The Contribution of Diet and Lifestyle Factors in the Prevalence of Irritable Bowel Syndrome

Authors: Alexander Dao, Oscar Wambuguh

Abstract:

Irritable Bowel Syndrome (IBS) is a heterogeneous functional bowel disease that is characterized by chronic visceral abdominal pain and abnormal bowel function and habits. Its multifactorial pathophysiology and mechanisms are still largely a mystery to the contemporary biomedical community, although there are many hypotheses to try to explain IBS’s presumed physiological, psychosocial, genetic, and environmental etiologies. IBS’s symptomatic presentation is varied and divided into four major subtypes: IBS-C, IBS-D, IBS-M, and IBS-U. Given its diverse presentation and unclear mechanisms, diagnosis is done through a combination of positive identification utilizing the “Rome IV Irritable Bowel Syndrome Criteria'' (Rome IV) diagnostic criteria while also excluding other potential conditions with similar symptoms. Treatment of IBS is focused on the management of symptoms using an assortment of pharmaceuticals, lifestyle changes, and dietary changes, with future potential in microbial treatment and psychotherapy as other therapy methods. Its chronic, heterogeneous nature and disruptive gastrointestinal (GI) symptoms are negatively impactful on patients’ daily lives, health systems, and society. However, with a better understanding of the gaps in knowledge and technological advances in IBS’s pathophysiology, management, and treatment options, there is optimism for the millions of people worldwide who are suffering from the debilitating effects of IBS.

Keywords: Irritable bowel syndrome, lifestyle, diet, functional gastrointestinal disorder.

References:

[1] W. D. Chey, J. Kurlander, and S. Eswaran. Irritable Bowel Syndrome: A Clinical Review. JAMA, 2015, vol. 313(9), pp. 949-958. doi: 10.1001/jama.2015.0954
[2] M. El-Salhy. Recent developments in the pathophysiology of irritable bowel syndrome. World Journal of Gastroenterology, 2015, vol. 21(25), pp. 7621-36. doi: 10.3748/wjg.v21.i25.7621
[3] K. Y. Huang, F. Y. Wang, M. Lv, X. X. Ma, X. D. Tang, and L. Lv. Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment. World Journal of Gastroenterology, 2023, vol. 29(26), pp. 4120-4135. doi: 10.3748/wjg.v29.i26.4120
[4] M. Camilleri. Diagnosis and Treatment of Irritable Bowel Syndrome: A Review. JAMA, 2021, vol. 325(9), pp. 865-877. doi: 10.1001/jama.2020.22532
[5] P. Moayyedi et al., Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. United European Gastroenterology Journal, 2017, vol. 5(6), pp. 773-788. doi: 10.1177/2050640617731968
[6] R. L. Soares. Irritable bowel syndrome: a clinical review. World Journal of Gastroenterology, 2014, vol. 20(34), pp. 12144-60. doi: 10.3748/wjg.v20.i34.12144
[7] L. Saha. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World Journal of Gastroenterology, 2014, vol. 20(22), pp. 6759-73. doi: 10.3748/wjg.v20.i22.6759
[8] M. Corsetti and P. Whorwell. The global impact of IBS: time to think about IBS-specific models of care? Therapeutic Advances in Gastroenterology, 2017, vol. 10(9), pp. 727-736. doi: 10.1177/1756283X17718677
[9] Y. Bhattarai, D. A. Muniz Pedrogo, and P. C. Kashyap. Irritable bowel syndrome: a gut microbiota-related disorder? American Journal of Physiology-Gastrointestinal and Liver Physiology, 2016, vol. 312(1), pp. G52-G62. doi: 10.1152/ajpgi.00338.2016
[10] A. Pietrzak et al., Guidelines on the management of irritable bowel syndrome. Gastroenterology Review, 2018, vol. 13(4), pp. 259-288. doi: 10.5114/pg.2018.78343.
[11] M. El-Salhy, J. G. Hatlebakk, and T. Hausken. Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones. Nutrients, 2019, vol. 11(8). doi: 10.3390/nu11081824
[12] T. A. Mudyanadzo, C. Hauzaree, O. Yerokhina, N. N. Architha, and H. M. Ashqar. Irritable Bowel Syndrome and Depression: A Shared Pathogenesis. Cureus, 2018, vol. 10(8), pp. e3178. doi: 10.7759/cureus.3178
[13] Q. X. Ng, A. Y. S. Soh, W. Loke, D. Y. Lim, and W. S. Yeo. The role of inflammation in irritable bowel syndrome (IBS). Journal of Inflammation Research, 2018, vol. 11, pp. 345-349. doi: 10.2147/jir.s174982
[14] N. Kanuri et al., The impact of abuse and mood on bowel symptoms and health-related quality of life in irritable bowel syndrome (IBS). Neurogastroenterology & Motility, 2016, vol. 28(10), pp. 1508-1517. doi: 10.1111/nmo.12848
[15] B. E. Lacy et al., ACG Clinical Guideline: Management of Irritable Bowel Syndrome. American Journal of Gastroenterology, 2021, vol. 116(1), pp. 17–44. doi: 10.14309/ajg.0000000000001036
[16] C. Catassi et al., The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update. Nutrients, 2017, vol. 9(11). doi: 10.3390/nu9111268
[17] M. El-Salhy, J. G. Hatlebakk, O. H. Gilja, and T. Hausken. The relation between celiac disease, nonceliac gluten sensitivity and irritable bowel syndrome. Nutrition Journal, 2015, vol. 14(1), pp. 92. doi: 10.1186/s12937-015-0080-6
[18] J. Yan et al., Acupuncture plus Chinese Herbal Medicine for Irritable Bowel Syndrome with Diarrhea: A Systematic Review and Meta-Analysis. Evidence-Based Complementary and Alternative Medicine, 2019, vol. 2019, pp. 7680963. doi: 10.1155/2019/7680963
[19] C. Zhou, E. Zhao, Y. Li, Y. Jia, and F. Li. Exercise therapy of patients with irritable bowel syndrome: A systematic review of randomized controlled trials. Neurogastroenterology & Motility, 2019, vol. 31(2), pp. e13461. doi: 10.1111/nmo.13461
[20] M. El-Salhy, J. G. Hatlebakk, and T. Hausken. Possible role of peptide YY (PYY) in the pathophysiology of irritable bowel syndrome (IBS). Neuropeptides, 2020, vol. 79, pp. 101973. doi: 10.1016/j.npep.2019.101973
[21] K. Dénes Botond, S. Andrea, H. Andras Gabor, and P. Olafur. Prevalence, epidemiology and associated healthcare burden of Rome IV irritable bowel syndrome and functional dyspepsia in the adult population of Gibraltar. BMJ Open Gastroenterology, 2022, vol. 9(1), pp. e000979. doi: 10.1136/bmjgast-2022-000979
[22] A. C. Ford, B. E. Lacy, L. A. Harris, E. M. M. Quigley, and P. Moayyedi. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. The American Journal of Gastroenterology, 2019, vol. 114(1), pp. 21-39. doi: 10.1038/s41395-018-0222-5
[23] D. Currò, G. Ianiro, S. Pecere, S. Bibbò, and G. Cammarota. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. British Journal of Pharmacology, 2017, vol. 174(11), pp. 1426-1449. doi: 10.1111/bph.13632
[24] A. Acosta et al., Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome. Clinical and Translational Gastroenterology, 2016, vol. 7(5), pp. e173. doi: 10.1038/ctg.2016.32
[25] O. C. Aroniadis et al., Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial. The Lancet Gastroenterology and Hepatology, 2019, vol. 4(9), pp. 675-685. doi: 10.1016/s2468-1253(19)30198-0
[26] O. S. Palsson, W. Whitehead, H. Törnblom, A. D. Sperber, and M. Simren. Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. Gastroenterology, 2020, vol. 158(5), pp. 1262-1273.e3. doi: 10.1053/j.gastro.2019.12.021
[27] S. Ballou and L. Keefer. The impact of irritable bowel syndrome on daily functioning: Characterizing and understanding daily consequences of IBS. Neurogastroenterology & Motility, 2017, vol. 29(4), pp. e12982. doi: 10.1111/nmo.12982